Immunotherapies such as chimeric antigen receptor (CAR) T cell therapy show a lot of promise to treat patients with various types of cancer. Developing a successful immunotherapy is challenging because patients show variable response rates and can develop therapy-induced toxicity or resistance. Recent technological advances now allow researchers to profile immune and cancer cell responses at the single-cell level, which helps them better understand the mechanisms underlying heterogeneous immunotherapy responses.
Download this research highlight from 10x Genomics to discover recent breakthroughs in CAR T therapeutic development.
The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com
© 1986-2022 The Scientist
The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.